Company news
Ardelyx, Inc. news in 2025
Ardelyx, Inc.'s news releases, calls and decks from 2025, newest first.
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
November 6, 2025
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
November 4, 2025
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
November 3, 2025
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 29, 2025
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
October 27, 2025
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
October 20, 2025
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
October 12, 2025
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
October 12, 2025
Ardelyx to Participate in Upcoming Investor Conferences
August 24, 2025
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors
August 12, 2025
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
August 3, 2025
Ardelyx Announces Changes to the Executive Leadership Team
August 3, 2025
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
July 20, 2025
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
June 1, 2025
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
May 20, 2025
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
May 5, 2025
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
April 30, 2025
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
April 28, 2025
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
April 23, 2025
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
April 16, 2025
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
April 9, 2025
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
March 30, 2025
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
March 12, 2025
Tenapanor Approved in China for Hyperphosphatemia
February 26, 2025
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 19, 2025
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
February 18, 2025
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
January 29, 2025
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
January 12, 2025
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 5, 2025
Calls in 2025
Decks in 2025
- Q2 2025 Earnings Presentation
Earnings · 22 slides · Aug 4, 2025